Teijin and NeuroSigma Enter into Exclusive License Agreement

Teijin Pharma to Market eTNS for the Treatment of ADHD in Japan LOS ANGELES, Oct. 17, 2019 -- (Healthcare Sales & Marketing Network) -- Teijin Limited (Teijin) and NeuroSigma, Inc. (NeuroSigma), a Los Angeles-based bioelectronics company focused on dev... Devices, Neurology, Licensing NeuroSigma, Teijin, Trigeminal Nerve Stimulation, Monarch eTNS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news